250 related articles for article (PubMed ID: 29133560)
1. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.
Bjugård Nyberg H; Draper HR; Garcia-Prats AJ; Thee S; Bekker A; Zar HJ; Hooker AC; Schaaf HS; McIlleron H; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871093
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
Thee S; Garcia-Prats AJ; McIlleron HM; Wiesner L; Castel S; Norman J; Draper HR; van der Merwe PL; Hesseling AC; Schaaf HS
Antimicrob Agents Chemother; 2014 May; 58(5):2948-51. PubMed ID: 24550337
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
[TBL] [Abstract][Full Text] [Related]
12. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
Savic RM; Ruslami R; Hibma JE; Hesseling A; Ramachandran G; Ganiem AR; Swaminathan S; McIlleron H; Gupta A; Thakur K; van Crevel R; Aarnoutse R; Dooley KE
Clin Pharmacol Ther; 2015 Dec; 98(6):622-9. PubMed ID: 26260983
[TBL] [Abstract][Full Text] [Related]
13. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
[TBL] [Abstract][Full Text] [Related]
14. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
Peloquin CA; Phillips PPJ; Mitnick CD; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Kaur P; Horsburgh CR
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012767
[TBL] [Abstract][Full Text] [Related]
15. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.
van den Elsen SHJ; Sturkenboom MGG; Van't Boveneind-Vrubleuskaya N; Skrahina A; van der Werf TS; Heysell SK; Mpagama S; Migliori GB; Peloquin CA; Touw DJ; Alffenaar JC
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30373800
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
Thee S; Garcia-Prats AJ; Draper HR; McIlleron HM; Wiesner L; Castel S; Schaaf HS; Hesseling AC
Clin Infect Dis; 2015 Feb; 60(4):549-56. PubMed ID: 25362206
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
